(ASMB) Assembly Biosciences - NASDAQ

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 460m USD | Total Return: 32.1% in 12m

Antivirals, Viral Therapeutics, Clinical Candidates
Total Rating 24
Safety 48
Buy Signal -0.82
Biotechnology
Industry Rotation: -7.2
Market Cap: 460M
Avg Turnover: 4.22M
Risk 3d forecast
Volatility61.0%
VaR 5th Pctl9.82%
VaR vs Median-2.23%
Reward TTM
Sharpe Ratio0.70
Rel. Str. IBD14.5
Rel. Str. Peer Group13.8
Character TTM
Beta1.225
Beta Downside0.849
Hurst Exponent0.411
Drawdowns 3y
Max DD57.49%
CAGR/Max DD0.36
CAGR/Mean DD1.09
EPS (Earnings per Share) EPS (Earnings per Share) of ASMB over the last years for every Quarter: "2021-06": -0.55, "2021-09": -0.41, "2021-12": -0.38, "2022-03": -0.48, "2022-06": -0.51, "2022-09": -0.48, "2022-12": -0.46, "2023-03": -0.37, "2023-06": -0.32, "2023-09": -0.27, "2023-12": -2.15, "2024-03": -1.66, "2024-06": -2.05, "2024-09": -1.51, "2024-12": -1.57, "2025-03": -1.17, "2025-06": -1.33, "2025-09": -0.72, "2025-12": 2.48, "2026-03": -0.54,
Last SUE: 0.09
Qual. Beats: 0
Revenue Revenue of ASMB over the last years for every Quarter: 2021-06: 0, 2021-09: 6.254, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 7.163, 2024-03: 5.785, 2024-06: 8.533, 2024-09: 6.845, 2024-12: 7.357, 2025-03: 9.419, 2025-06: 9.626, 2025-09: 10.789, 2025-12: 42.469, 2026-03: 8.212999,
Rev. CAGR: 217.71%
Rev. Trend: 99.4%
Last SUE: 0.11
Qual. Beats: 0

Warnings

P/E ratio 290.4

Share dilution 125.1% YoY

High Debt while negative Cash Flow

Altman Z'' -0.96 < 1.0 - financial distress zone

Fakeout

Tailwinds

No distinct edge detected

Description: ASMB Assembly Biosciences

Assembly Biosciences, Inc. (ASMB) is a biotechnology firm specializing in the development of small-molecule antiviral therapeutics. The companys current pipeline focuses on long-acting treatments for recurrent genital herpes, chronic hepatitis delta virus (HDV), and chronic hepatitis B virus (HBV). Its lead candidates, including ABI-5366 and ABI-6250, are currently in Phase 1 clinical evaluations.

The company operates under a research-driven business model typical of the biotechnology sector, where high R&D expenditures are often offset by strategic partnerships. Assembly Biosciences maintains a significant collaboration agreement with Gilead Sciences, Inc. to co-develop virology therapies, providing the firm with additional technical resources and potential milestone payments. In the biotech industry, such collaborations are critical for mitigating the financial risks associated with long-term clinical trial cycles.

Investors can further evaluate the companys financial health and pipeline progress by reviewing the detailed metrics available on ValueRay. Assembly Biosciences remains headquartered in South San Francisco, a primary global hub for life sciences innovation and venture capital investment.

Headlines to Watch Out For
  • Gilead partnership milestone payments and equity investments provide critical non-dilutive capital
  • Clinical trial data readouts for recurrent genital herpes candidates drive immediate valuation
  • Regulatory progression of orally bioavailable HDV and HBV inhibitors impacts long-term growth
  • R&D expenditure and cash burn rates dictate future equity financing necessity
  • Competition within the chronic hepatitis treatment landscape influences market share expectations
Piotroski VR-10 (Strict) 0.5
Net Income: -6.38m TTM > 0 and > 6% of Revenue
FCF/TA: -0.17 > 0.02 and ΔFCF/TA 39.85 > 1.0
NWC/Revenue: 278.0% < 20% (prev 152.1%; Δ 125.9% < -1%)
CFO/TA -0.17 > 3% & CFO -39.8m > Net Income -6.38m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.65 > 1.5 & < 3
Outstanding Shares: last quarter (16.9m) vs 12m ago 125.1% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 42.51% > 50% (prev 32.47%; Δ 10.03% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' -0.96
A: 0.84 (Total Current Assets 232.6m - Total Current Liabilities 35.0m) / Total Assets 235.5m
B: -3.57 (Retained Earnings -841.1m / Total Assets 235.5m)
C: -0.07 (EBIT TTM -11.9m / Avg Total Assets 167.3m)
D: 5.38 (Book Value of Equity 198.6m / Total Liabilities 36.9m)
Altman-Z'' = -0.96 = CCC
Beneish M -2.89
DSRI: 0.51 (Receivables 451k/400k, Revenue 71.1m/32.2m)
GMI: 1.00 (GM 99.60% / 99.82%)
AQI: 0.42 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 2.21 (Revenue 71.1m / 32.2m)
TATA: 0.14 (NI -6.38m - CFO -39.8m) / TA 235.5m)
Beneish M = -2.89 (Cap -4..+1) = A
What is the price of ASMB shares?

As of June 12, 2026, the stock is trading at USD 22.53 with a total of 290,541 shares traded.
Over the past week, the price has changed by -6.55%, over one month by -25.91%, over three months by -22.87% and over the past year by +32.14%.

Is ASMB a buy, sell or hold?

Assembly Biosciences has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ASMB.

  • StrongBuy: 2
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ASMB price?
Analysts Target Price 48.8 116.4%
Assembly Biosciences (ASMB) - Fundamental Data Overview as of 09 June 2026
Market Cap USD = 460.4m (460.4m USD * 1.0 USD.USD)
P/E Trailing = 290.375
P/E Forward = 13.0208
P/S = 6.475
P/B = 2.2879
Revenue TTM = 71.1m USD
EBIT TTM = -11.9m USD
EBITDA TTM = -11.8m USD
Long Term Debt = 1.90m USD (estimated: total debt 2.49m - short term 590k)
Short Term Debt = 590k USD (from shortTermDebt, last quarter)
Debt = 2.49m USD (from shortLongTermDebtTotal, last quarter) (leases 2.49m already included)
Net Debt = -224.1m USD (calculated: Debt 2.49m - CCE 226.6m)
Enterprise Value = 236.2m USD (460.4m + Debt 2.49m - CCE 226.6m)
 Interest Coverage Ratio = unknown (Ebit TTM -11.9m / Interest Expense TTM 0.0)
 EV/FCF = -5.93x (Enterprise Value 236.2m / FCF TTM -39.8m)
FCF Yield = -16.86% (FCF TTM -39.8m / Enterprise Value 236.2m)
FCF Margin = -56.03% (FCF TTM -39.8m / Revenue TTM 71.1m)
Net Margin = -8.98% (Net Income TTM -6.38m / Revenue TTM 71.1m)
 Gross Margin = unknown ((Revenue TTM 71.1m - Cost of Revenue TTM 129k) / Revenue TTM)
 Tobins Q-Ratio = 1.00 (Enterprise Value 236.2m / Total Assets 235.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.49m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -9.39m (EBIT -11.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.65 (Total Current Assets 232.6m / Total Current Liabilities 35.0m)
Debt / Equity = 0.01 (Debt 2.49m / totalStockholderEquity, last quarter 198.6m)
 Debt / EBITDA = 19.05 (negative EBITDA) (Net Debt -224.1m / EBITDA -11.8m)
 Debt / FCF = 5.63 (negative FCF - burning cash) (Net Debt -224.1m / FCF TTM -39.8m)
 Total Stockholder Equity = 151.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.82% (Net Income -6.38m / Total Assets 235.5m)
RoE = -4.21% (Net Income TTM -6.38m / Total Stockholder Equity 151.5m)
RoCE = -7.75% (EBIT -11.9m / Capital Employed (Equity 151.5m + L.T.Debt 1.90m))
 RoIC = -4.75% (negative operating profit) (NOPAT -9.39m / Invested Capital 197.5m)
 WACC = 10.23% (E(460.4m)/V(462.8m) * Re(10.29%) + D(2.49m)/V(462.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 64.92%
 [DCF] Fair Price = unknown (Cash Flow -39.8m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.09 | # QB: 0
Revenue Correlation: 99.37 | Revenue CAGR: 217.7% | SUE: 0.11 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.53 | Chg30d=+22.42% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.51 | Chg30d=+24.63% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.14 | Chg30d=+111.41% | Revisions=+33% | GrowthEPS=+125.4% | GrowthRev=-19.8%
EPS next Year (2027-12-31): EPS=-2.71 | Chg30d=-17.32% | Revisions=-33% | GrowthEPS=-2035.7% | GrowthRev=-44.4%
[Analyst] Revisions Ratio: +33%